{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-097239","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.261213+00:00","generated_at":"2026-06-30T01:11:38.490637+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck Q2 sales $11.4B (+22% YoY); raises full-year revenue guidance to $46.4B-$47.4B","bullets":["GAAP EPS $0.48; non-GAAP EPS $1.31, up 28% YoY on strong demand recovery.","KEYTRUDA sales $4.2B (+23%); GARDASIL $1.2B (+88%) driven by pandemic recovery.","Completed Organon spinoff on June 2; received ~$9B cash distribution.","Full-year non-GAAP EPS guidance raised to $5.47-$5.57, including ~2% FX benefit.","FDA approvals for VAXNEUVANCE, KEYTRUDA in TNBC and endometrial carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-097239","json":"https://secwatch.observer/filing/0001104659-21-097239.json","markdown":"https://secwatch.observer/filing/0001104659-21-097239.md","text":"https://secwatch.observer/filing/0001104659-21-097239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465921097239/0001104659-21-097239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465921097239/tm2123400d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T01:11:38.490637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}